Pembrolizumab biomarkers for solid cancer

Background on these biomarkers

Pembrolizumab has a broad approval for use in metastatic solid cancers that have high TMB or MSI.

Your biomarker results

You have been tested for TMB, one of the two approved tissue-agnostic biomarkers for prescribing Pembrolizumab. You have not been tested for the other biomarker, MSI.

• TMB: You have been measured as having a high tumor mutational burden. Combined with your clinical history, high TMB makes you eligible to take Pembrolizumab, under the FDA accelerated solid tumor approval. While elevated TMB is uncommon (<5% of patients) in prostate cancer, there is evidence that some CRPC patients respond well to pembrolizumab.

Your detailed results for this biomarker group